Scienmag

NOVEMBER 16, 2020

Singapore scientists uncover potential role of long non-coding RNAs in pancreatic cancer Credit: From Figure 4 in Liu, S., Wnt-regulated lncRNA discovery enhanced by in vivo identification and CRISPRi functional validation. Harmston, N., Glaser, T.L. Genome Med 12, 89 (2020).

In-Vivo 53

In-Vivo RNA DNA Genome 53

XTalks

APRIL 6, 2022

Cancerous cells and tumors release small fragments of DNA into the bloodstream called circulating tumour DNA (ctDNA). The researchers at the Cancer Research UK Cambridge Institute published this data from the LUng cancer CIrculating tumour DNA (LUCID) study in the journal Annals of Oncology.

DNA 105

DNA In-Vitro Doctor Doctors 105

Pharmaceutical Technology

JUNE 4, 2023

Within the emerging innovation stage, cell therapy for ocular disorders, coronavirus vaccine components, and DNA polymerase compositions are disruptive technologies that are in the early stages of application and should be tracked closely.

Genetics 130

Genetics Gene Expression DNA Antibody 130

BioTech 365

FEBRUARY 5, 2021

Biotechnology, Pharma and Biopharma News – Research – Science – Lifescience ://Biotech-Biopharma-Pharma: At the core of the integrator complex.Gene expression is a highly regulated process that involves several steps. These include transcription of DNA instructions into RNA, removal of … Continue reading →

RNA 40

RNA DNA Regulation Research 40

Roots Analysis

AUGUST 31, 2023

Gene switches can be regulatory proteins or specific DNA sequences that act to either switch on or off the expression of a gene. Basic Components of Gene Switch Gene switches are composed of noncoding DNA sequences and transcription factors. Negative Gene Regulation: Repressor is a protein molecule that initiates negative regulation.

Gene 40

Gene Gene Therapy Gene Expression Regulation 40

The Pharma Data

MARCH 7, 2022

The new technique controls gene activity without altering the DNA sequence of the genome by targeting chemical modifications that help package genes in our chromosomes and regulate their activity. The chemical modifications that regulate gene activity are called epigenetic markers. Cas9 binds and uses RNA as an address-tag.

Protein 52

Protein Gene Genome Genomics 52

XTalks

MAY 4, 2021

The tool targets the epigenome, the collection of DNA modifications in a cell such as methylation and post-translational histone modifications. These modifications regulate gene expression without altering the sequence or structure of DNA. DNA methylation occurs endogenously in all mammalian cells in response to various stimuli.

DNA 52

DNA Gene Gene Silencing Genome 52

Roots Analysis

MARCH 8, 2023

INTRODUCTION TO EXOSOMES Exosomes are extracellular vesicles, which have endosomal origin and may contain different biomolecules, including proteins, DNA, lipids, miRNA or RNA , based on the type of cell of their origin and its conditions. Exosomes convey a wide range of information to the target cells, depending on their source.

RNA 52

RNA Drug Delivery DNA Development 52

XTalks

NOVEMBER 7, 2022

Liquid biopsy tests in oncology involve isolating entities such as circulating tumor cells (CTC), circulating tumor DNA (ctDNA) and tumor-derived exosomes. The cfDNA that originates from tumors is called circulating tumor DNA (ctDNA). Also, exosomes are mostly being used for the detection of circulating RNA and microRNA. “An

Clinical Trials 98

Clinical Trials Clinical Trials Trials FDA Approval 98

pharmaphorum

DECEMBER 21, 2020

But the tragic events of 2020 have meant these companies have become household names as their trailblazing mRNA vaccines became the first to be approved by regulators against the COVID-19 scourge. Their technology is based on synthetic messenger RNA – short for ribose nucleic acid – which is a short transcript of a longer DNA code.

Vaccine 111

Vaccine Vaccination Doctor Doctors 111

XTalks

AUGUST 12, 2020

Studies have identified the presence of two types of HIV-infected CD4+ T cells: ‘Transcriptionally inactive’ cells that do not typically produce viral RNA or viral proteins. Transcriptionally active’ cells in which HIV RNA is actively transcribed to make copies of the virus (despite long-term ART).

RNA 52

RNA Protein DNA In-Vivo 52

The Pharma Data

JANUARY 21, 2021

In the ATLAS study, CABENUVA met the primary endpoint for noninferiority (the proportion of participants with plasma HIV-1 RNA ?50 50 copies per milliliter [c/mL] at Week 48), with a comparable number of patients receiving either CABENUVA or their daily current antiretroviral regimen (CAR) having an HIV-1 RNA level ?50

FDA Approval 52

FDA Approval RNA Drugs Containment 52

Pfizer

AUGUST 15, 2022

Nirmatrelvir is designed to inhibit viral replication at a stage known as proteolysis, which occurs before viral RNA replication. In preclinical studies, nirmatrelvir did not demonstrate evidence of mutagenic DNA interactions. Cystic fibrosis transmembrane conductance regulator potentiators: lumacaftor/ivacaftor.

Drugs 99

Drugs Vaccine Vaccination In-Vitro 99

Pfizer

DECEMBER 13, 2022

Nirmatrelvir is designed to inhibit viral replication at a stage known as proteolysis, which occurs before viral RNA replication. In preclinical studies, nirmatrelvir did not demonstrate evidence of mutagenic DNA interactions. Cystic fibrosis transmembrane conductance regulator potentiators: lumacaftor/ivacaftor.

Drugs 110

Drugs Licensing Licensing Production 110

WCG Clinical

MAY 28, 2024

When properly regulated these cellular features—proliferative capacity and receptor-directed specificity—largely account for the effectiveness of our adaptive immune system in protecting us from infectious disease. The level of such antinuclear antibodies often correlates with the severity of disease.

In-Vivo 40

In-Vivo Clinical Trials Clinical Trials FDA Approval 40

Pfizer

JANUARY 27, 2023

Nirmatrelvir is designed to inhibit viral replication at a stage known as proteolysis, which occurs before viral RNA replication. In preclinical studies, nirmatrelvir did not demonstrate evidence of mutagenic DNA interactions. John’s Wort ( hypericum perforatum ) There are limited clinical data available for PAXLOVID.

Marketing 75

Marketing Production Drugs Licensing 75

Pfizer

DECEMBER 20, 2022

Nirmatrelvir is designed to inhibit viral replication at a stage known as proteolysis, which occurs before viral RNA replication. In preclinical studies, nirmatrelvir did not demonstrate evidence of mutagenic DNA interactions. Cystic fibrosis transmembrane conductance regulator potentiators: lumacaftor/ivacaftor.

Drugs 69

Drugs Licensing Licensing Containment 69

The Pharma Data

AUGUST 3, 2021

The company and MiNA Therapeutics Limited announced a global research collaboration to develop novel drug candidates using MiNA’s proprietary small activating RNA (saRNA) technology platform. Business Development/Other Developments. The company announced the acquisition of Protomer Technologies Inc.,

Antibody 52

Antibody Sales Development Production 52

The Pharma Data

APRIL 30, 2021

Under the multi-year agreement, AbbVie will utilize Caribou’s next-generation Cas12a CRISPR hybrid RNA-DNA genome editing and cell therapy technologies to research and develop two new CAR-T cell therapies directed to targets specified by AbbVie. AbbVie and Caribou Biosciences, Inc., Full-Year 2021 Outlook.

Botox 40

Botox Production Development Cosmetics 40

XTalks

AUGUST 2, 2023

In September 2022, Roche acquired Good Therapeutics for an upfront payment of $250 million, and has access to their PD-1-regulated IL-2 program. The TPO receptor agonist regulates blood platelet production by binding to and activating TPO receptors on megakaryocyte cells and inducing signalling cascades that increase platelet production.

Sales 98

Sales Manufacturing FDA Approval Life Science 98

Pfizer

NOVEMBER 23, 2022

Nirmatrelvir is designed to inhibit viral replication at a stage known as proteolysis, which occurs before viral RNA replication. In preclinical studies, nirmatrelvir did not demonstrate evidence of mutagenic DNA interactions. Cystic fibrosis transmembrane conductance regulator potentiators: lumacaftor/ivacaftor.

Licensing 40

Licensing Licensing Drugs Manufacturing 40

The Pharma Data

MAY 13, 2021

Stimulates DNA and RNA synthesis. Carl was taking ibuprofen and opiates to manage the pain, but knew he had to be careful to regulate it because of the kidney and liver problems it could cause. Increases your energy levels by increasing ATP production. Activates and speeds up the lymphatic system.

Production 52

Production Pharmacy Doctor Doctors 52

XTalks

DECEMBER 24, 2020

BioNTech/Pfizer’s vaccine became the world’s first approved COVID-19 vaccine, with UK regulators becoming the first to authorize it for emergency use, followed by Health Canada, which fully approved it. The system can be used to precisely edit out portions of DNA flanked by CRISPR sequences. Single-Cell RNA Sequencing.

Life Science 111

Life Science Vaccine Vaccination Gene 111

pharmaphorum

DECEMBER 2, 2020

Other false claims are that RNA-based vaccines like BNT162b can alter a recipient’s DNA and that the shots will contain tissue from aborted foetuses. The regulators are fiercely independent – they would not approve this if it wasn’t safe.”

Vaccine 105

Vaccine Vaccination Medicine RNA 105

Pharmaceutical Technology

APRIL 24, 2023

Since then, the field of nanomedicine has steadily progressed to reach high points such as the successful use of nanotechnology to deliver messenger RNA (mRNA)-based Covid-19 vaccines. Langer, now a David H. Conde says the use of nanoparticle delivery for gene therapies has become more common over recent years.

Drug Delivery 147

Drug Delivery Vaccination Vaccine Research 147

XTalks

FEBRUARY 27, 2025

SERENA-6 is unique as the first global, double-blind study to use circulating tumor DNA (ctDNA) monitoring a blood-based approach to detect early signs of endocrine resistance. By tracking small fragments of tumor DNA in the bloodstream, researchers identified the emergence of ESR1 mutations before clinical progression appeared.

Trials 59

Trials HR Clinical Trials Clinical Trials 59

XTalks

SEPTEMBER 14, 2020

The company’s candidate vaccine, mRNA-1273, is a synthetic messenger RNA that encodes the stabilized SARS-CoV-2 spike protein. Meanwhile, N95 masks are in such short supply that regulators have told healthcare workers they can be used multiple times with little evidence that disinfecting them works.

Vaccination 92

Vaccination Vaccine Antibody Life Science 92